ADULT PATIENTS W/ RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA

患有复发性或难治性 B 系急性淋巴细胞白血病的成年患者

• 批准号: 7605250
• 负责人: STEVEN E COUTRE
• 金额: $ 0.7万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605250
• 关键词: Acute; Acute Lymphocytic Leukemia; Adult; Antibodies; Cell Lineage; Complement; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Funding; Grant; Human; Immunoglobulin M; Institution; Lymphoblastic Leukemia; Monoclonal Antibodies; Patients; Phase I Clinical Trials; Refractory; Relapse; Research; Research Personnel; Resources; Safety; Source; United States National Institutes of Health; Vincristine; killings; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I trial of a human IgM monoclonal antibody (MAb216) that kills B lineage cells including acute B lymphoblastic leukemia, with or without complement. Trial will study safety, pharmacokinetics and anti-tumor activity of the antibody given as a single agent and with vincristine in adult patients with relapsed or refractory B lineage ALL.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 一种人IgM单抗(MAb216)的I期试验，该抗体可以杀死包括急性B淋巴细胞性白血病在内的B系细胞，无论有没有补体。试验将研究该抗体作为单一药物和长春新碱联合应用于复发或难治性B系ALL成人患者的安全性、药代动力学和抗肿瘤活性。